Ipratropium bromide enantiomer with prolonged duration of effect
Patent 6299861 Issued on October 9, 2001. Estimated Expiration Date: 
August 6, 2019. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
August 6, 2019. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.Patent ReferencesMethods for the treatment of nasal hypersecretion Medicinal aerosol formulations Patent #: 5225183 InventorsAssigneeApplicationNo. 369711 filed on 08/06/1999US Classes:424/45, Organic pressurized fluid424/46, Powder or dust containing424/434, Mucosal (e.g., nasal, etc.)424/489Particulate form (e.g., powders, granules, beads, microcapsules, and pellets)ExaminersPrimary: Page, Thurman K.Assistant: Pulliam, Amy E Attorney, Agent or FirmInternational ClassesA61L 009/04A61K 009/14 A61F 013/00 Foreign Application Priority Data1995-08-01 DEAbstractOn account of the surprisingly powerful and long-lasting effect thereof, the salts of the L-(-)-enantiomer of (endo, syn)-(-)-3-(3-hydroxy-1-oxo-2-phenylpropoxy)-8-methyl-8-(methylethyl)-8-az oniabicyclo [3,2,1]octane are suitable as active substances for drugs administered by inhalation for respiratory tract therapy.Other References
| |
